학술논문
Pembrolizumab With or Without Lenvatinib for First-Line Metastatic NSCLC With Programmed Cell Death-Ligand 1 Tumor Proportion Score of at least 1% (LEAP-007): A Randomized, Double-Blind, Phase 3 Trial
Document Type
Article
Author
Yang, James Chih-Hsin; Han, Baohui; De La Mora Jiménez, Emmanuel; Lee, Jong-Seok; Koralewski, Piotr; Karadurmus, Nuri; Sugawara, Shunichi; Livi, Lorenzo; Basappa, Naveen S.; Quantin, Xavier; Dudnik, Julia; Ortiz, Diego Moran; Mekhail, Tarek; Okpara, Chinyere E.; Dutcus, Corina; Zimmer, Zachary; Samkari, Ayman; Bhagwati, Niyati; Csőszi, Tibor
Source
In Journal of Thoracic Oncology June 2024 19(6):941-953
Subject
Language
ISSN
1556-0864